Karyopharm Therapeutics Inc logo

Karyopharm Therapeutics Inc

NAS:KPTI (USA)  
$ 1.05 -0.04 (-3.67%) 10:08 PM EST
At Loss
Market Cap:
$ 123.60M
Enterprise V:
$ 151.45M
Volume:
939.66K
Avg Vol (2M):
1.21M
Also Trade In:
Volume:
939.66K
At Loss
Avg Vol (2M):
1.21M

Business Description

Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.84
Equity-to-Asset -0.83
Debt-to-Equity -1.04
Debt-to-EBITDA -1.45
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -10.74
Distress
Grey
Safe
Beneish M-Score -2.12
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 24.49
9-Day RSI 37.14
14-Day RSI 41.29
6-1 Month Momentum % 47.62
12-1 Month Momentum % -56.4

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.04
Quick Ratio 2.99
Cash Ratio 2.27
Days Inventory 217.81
Days Sales Outstanding 84.95
Days Payable 271.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -15.8
Shareholder Yield % 1.62

Financials (Next Earnings Date:2024-08-02 Est.)

KPTI's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:KPTI

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Karyopharm Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 140.461
EPS (TTM) ($) -1.27
Beta 0.36
Volatility % 97.74
14-Day RSI 41.29
14-Day ATR ($) 0.092292
20-Day SMA ($) 1.09925
12-1 Month Momentum % -56.4
52-Week Range ($) 0.6174 - 2.47
Shares Outstanding (Mil) 117.71

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Karyopharm Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Karyopharm Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Karyopharm Therapeutics Inc Frequently Asked Questions

What is Karyopharm Therapeutics Inc(KPTI)'s stock price today?
The current price of KPTI is $1.05. The 52 week high of KPTI is $2.47 and 52 week low is $0.62.
When is next earnings date of Karyopharm Therapeutics Inc(KPTI)?
The next earnings date of Karyopharm Therapeutics Inc(KPTI) is 2024-08-02 Est..
Does Karyopharm Therapeutics Inc(KPTI) pay dividends? If so, how much?
Karyopharm Therapeutics Inc(KPTI) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1